Trial record 2 of 11 for:    snx5422

Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

This study has been terminated.
(Business reasons)
Sponsor:
Information provided by (Responsible Party):
Esanex Inc.
ClinicalTrials.gov Identifier:
NCT01848756
First received: May 3, 2013
Last updated: July 13, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)